Evan Lippman

Evan Lippman was appointed Executive Vice President of Business Development in March 2025, to lead the company’s business development, licensing and alliance management functions.  In this role, Evan’s remit is to accelerate Teva's momentum bringing innovative therapies to patients worldwide through strategic partnerships and collaborations across the academic, healthcare and technology sectors.

Evan is an accomplished executive with extensive experience in corporate finance, business development and operational leadership across both large pharmaceutical companies and emerging biotechnology firms. He joins us from Alnylam Pharmaceuticals, where he served as Chief Corporate Development & Strategy Officer. In this role, Evan led a team focused on defining and implementing strategic priorities, identifying and negotiating external transactions, and managing complex partnership obligations.

Before Alnylam, Evan was President & Chief Operating Officer at Intima Bioscience. Prior to that, he held the role of Senior Vice President, Head of Corporate Development, M&A and Valuation at Takeda Pharmaceuticals, where he successfully spearheaded global acquisitions, divestments, licensing, and strategic collaborations.

Evan’s leadership experience also includes serving as Chief Business & Financial Officer at Aileron Therapeutics, a clinical stage oncology company. His commercial and operational expertise was further honed at EMD Serono and AstraZeneca, where he served as General Manager, overseeing three multi-billion-dollar revenue-generating business units for Rebif, Crestor and Nexium. Earlier in his career, Evan held senior business development roles at AstraZeneca and Pfizer.

Evan began his professional journey as an investment banker, advising companies on M&A, leveraged buyouts and capital market transactions. He holds an MBA from Cornell University.